Commercial strategy
Indication prioritization and asset assessment
Which indication should come next? We compare the options on the same patients, the same competitors and the same assumptions.
What we do
The largest disease population is not always the best opportunity. What matters is who would qualify for treatment, what those patients receive today and which competitors could get there first.
We build each candidate indication on one consistent structure, so the comparison reflects the opportunities and not differences in method. The result is a ranked view, with the main uncertainties and what would change the answer.
Before NextIndication, our team built epidemiology models across 12 oncology projects and patient-based forecasts for more than ten oncology assets.
How it works
Four steps, nothing hidden.
- 1
Frame
Agree the candidate indications and the criteria that matter to your decision.
- 2
Model
Build a patient model and forecast for each indication on one structure.
- 3
Compare
Rank the options and show what drives the differences.
- 4
Brief
Deliver a decision brief with the uncertainties and next evidence needs.
Questions teams ask
Before you start.
How many indications can you compare at once?
We work with a bounded set, usually the handful a team is seriously considering, so each one gets a real patient model instead of a headline number.
What do you need from us to start?
The asset's target profile, the indications under consideration and any existing forecasts or research. Public sources cover epidemiology, treatment patterns and the pipeline.
Do you make the final decision?
No. We provide the analysis, the comparison and the main uncertainties. The decision stays with your team.
Related services
This usually connects to
What's your next indication?
Tell us the decision in front of you. We will tell you what it takes to answer it.